Site News  |   Monitor Keywords  |   Monitor Archive  |   Organizer  |   Account Info  |

Phenazine compounds and use thereof in autoimmune and inflammatory disease

Phenazine compounds and use thereof in autoimmune and inflammatory disease description/claims

This application claims the benefit of and claims from U.S. provisional Application Ser. No. 60/885,164 filed Jan. 16, 2007, which is incorporated herein by reference in its entirety.

The present invention relates to novel water-soluble phenazine compounds, and their use in the treatment of autoimmune diseases and inflammatory diseases.

Arthritis (from the Greek word for joint) is a chronic multifactorial disease induced when the immune system attacks and begins degrading the body's joints. Rheumatoid arthritis (RA) is characterized by chronic inflammation of the synovium, and comes in many forms, including calcific periarthritis, enteropathic arthritis, chronic, gouty, and hand osteoarthritis, hip and knee osteoarthritis, thumb, Jaccoud's, juvenile osteoarthritis, oligoarthritis, polyarthritis, and peripheral, psoriatic, rheumatoid, and septic arthritis. RA is triggered by an immune response generated via the molecular recognition of the T-cell receptor on CD4-positive T cells with a complex of disease-inducing peptides bound to Human Leukocyte Antigen (HLA) class II molecules.

Rheumatoid arthritis alone is estimated to affect 1% of the world's population and is twice as prevalent in women as in men. The aging population of developed countries are presents a growing market for arthritis therapies. In the US, arthritis and other rheumatic conditions affects about 15% of the population.

Rheumatoid arthritis is associated with the expression of certain HLA class II molecules. It is known that blockade of the interaction between a given class II molecule, peptide ligand, and T cell receptor inhibits specific T cell responses both in vitro and in vivo. Tumor necrosis factor α (TNFα), an inflammation-promoting cytokine is found associated with multiple inflammatory events, including arthritis, and anti-TNFα therapeutics include Enbrel® (Etanercept), Humira® (Adalimumab), and Remicade® (Infliximab).

Other therapeutic strategies which are directed at the T cell, such as total lymphoid irradiation, thoracic duct drainage, cyclosporin A, anti-CD4 monoclonal antibody, and other monoclonal antibodies directed at T cell determinants, result in some cases in clinical improvement of rheumatoid arthritis, but these therapies are also associated with side effects. For instance, conventional general immunosuppressives increase the risk of opportunistic infections and cancer.

There is no cure for arthritis or RA at present. Current therapies are aimed at alleviating the symptoms of the disease and arresting its progress using drugs such as Enbrel®. Chemotherapeutic agents such as methotrexate, cyclophosphamide and cyclosporine have been also used for alleviating symptoms. All of the above treatments have side-effect liabilities, limited effects on relapse rates and on ability to prevent exacerbation of the disease.

Thus, there is a need for new drugs which can be used alone or in combination with other drugs to combat the progression and symptoms of arthritis, in particular, RA. It has now been found that certain novel phenazine compounds facilitate recovery in subjects suffering from autoimmune diseases. Thus, the novel phenazine compounds are useful in the treatment and prevention of arthritis, RA, and other autoimmune diseases.

The present invention provides compositions and methods for treating or preventing the onset of autoimmune diseases, inflammation, inflammation diseases, metabolic syndrome, dyslipidemia, cardiovascular diseases, disorders of the peripheral and central nervous system, hematological diseases, cancer, respiratory diseases, gastroenterological diseases, diabetes, and non-alcoholic fatty liver disease. The molecules and compositions of the invention can be delivered alone or in combination with additional agents, and are used as for the treatment or prevention of autoimmune diseases, inflammation diseases, and cardiovascular diseases.

Accordingly, in one aspect, the subject invention is directed to a method for treating or preventing autoimmune diseases in a subject in need thereof. The method comprises administering to the subject a pharmaceutically effective amount of a compound of Formula I, II, III, or IV:

where X1 and X3 are independently selected to be O− or S−; X2 and X4 are independently selected to be O, S, NH, NR5 or CHR5 where R5 can be a lower alkyl; R1 is selected from the group consisting of lower alkyl containing 1 to 10 carbon atoms, halo-lower alkyl, lower alkenyl, lower alkynyl, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylthio, lower alkylamino, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, or substituted heteroaryl; R2, R3 and R4 are independently selected to be hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, cyano, ether, halo, hydroxy, phosphate, phosphonate, sulfate, sulfonate, or sulfonamide; and M+ can be alkali metal ion such as sodium, lithium, and potassium, alkaline earth metal ion such as calcium and magnesium, or any other positively charged species that forms a pharmaceutically acceptable salt.

Continue reading about Phenazine compounds and use thereof in autoimmune and inflammatory disease...
Full patent description for Phenazine compounds and use thereof in autoimmune and inflammatory disease

Brief Patent Description - Full Patent Description - Patent Application Claims

Click on the above for other options relating to this Phenazine compounds and use thereof in autoimmune and inflammatory disease patent application.

Patent Applications in related categories:

20090298842 - Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor - Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for ...


###


How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Phenazine compounds and use thereof in autoimmune and inflammatory disease or other areas of interest.
###


Previous Patent Application:
Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
Next Patent Application:
Pyridazinyl amine derivatives, the use thereof in the preparation of picorna virus inhibitors
Industry Class:
Drug, bio-affecting and body treating compositions

###

• Provisional Patent
• Utility Patent

• What Is a Patent?
• What Is a Trademark or Servicemark?
• What Is a Copyright?
• Patent Laws